Cover Image

Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences

Abstract Background Clinical trials with dupilumab in atopic dermatitis (AD) patients showed a trend towards better effectiveness with a weekly or biweekly dosing interval, compared with extended dosing intervals. However, literature about adjusted dose regimens in daily practice is lacking. Objecti...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jill I. Olydam (Author), Linde E. M. deWijs (Author), Tamar E. C. Nijsten (Author), Joost vanRosmalen (Author), Dirk Jan Hijnen (Author)
Format:	Book
Published:	Wiley, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
by: Linde deWijs, et al.
Published: (2022)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
by: Amanda E. Zubek, MD, PhD, et al.
Published: (2021)

Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
by: Tiago Torres, et al.
Published: (2024)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023)

Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
by: Shan J, et al.
Published: (2022)

Alopecia areata after dupilumab for atopic dermatitis
by: Krystal Mitchell, MBA, et al.
Published: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
by: Sandra Ferreira, et al.
Published: (2020)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023)

Dupilumab normalizes correlates of lysosomal function in atopic dermatitis
by: Christina Bürgler, et al.
Published: (2024)

Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022)

Dupilumab for the treatment of alopecia areata in children with atopic dermatitis
by: Sung Kyung Cho, BA, et al.
Published: (2021)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022)

Immune Thrombocytopenic Purpura in a Patient with Atopic Dermatitis Treated with Dupilumab
by: Surina Frey, et al.
Published: (2021)

Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
by: Shoko Miyamoto, et al.
Published: (2022)

Eye Complications During Dupilumab Treatment for Severe Atopic Dermatitis
by: Lina U. Ivert, et al.
Published: (2019)

Conjunctivitis as a common adverse effect of dupilumab in atopic dermatitis
by: Mikołaj Cichoń, et al.
Published: (2023)

Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis
by: Shinji Mitsuyama, et al.
Published: (2023)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
by: Danielle M. Peterson, MD, et al.
Published: (2021)

Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis
by: Emilie Fowler, et al.
Published: (2019)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024)

Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
by: Marco Ferrari, et al.
Published: (2023)

Drug survival rate of dupilumab in Japanese patients with atopic dermatitis
by: Susumu Ichiyama, et al.
Published: (2021)

Dupilumab-induced phenotype switching from atopic dermatitis to psoriasis
by: Aakaash Varma, BA, et al.
Published: (2020)

A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children
by: Wang M, et al.
Published: (2024)

Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2022)

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020)

443 Dupilumab for Children and Adolescents with Atopic Dermatitis: An Asian Perspective
by: Shi Yun Chia, et al.
Published: (2021)

Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: Retrospective, Observational Cohort Study
by: Torunn E Sivesind, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
by: Kim Rand, et al.
Published: (2023)

Purpuric Drug Eruption in a Patient with Atopic Dermatitis Treated with Dupilumab
by: Mingxia Wang, et al.
Published: (2022)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
by: Marissa Ayasse, BS, et al.
Published: (2021)

Improvement of atopic dermatitis and alopecia universalis with dupilumab: a case report
by: Lama Alotaibi, et al.
Published: (2021)

Dupilumab for atopic dermatitis treatment: A single-center retrospective study
by: Gülbin Yaşar, et al.
Published: (2022)

Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis,
by: Camilla Chello, et al.
Published: (2021)

Alopecia areata-like and psoriasis after dupilumab use for atopic dermatitis,
by: Viviane Maria Maiolini, et al.
Published: (2021)

Diagnosis of Mycosis Fungoides Following Administration of Dupilumab for Misdiagnosed Atopic Dermatitis
by: Takahito Chiba, et al.
Published: (2019)

Real‐world use of dupilumab for 53 patients with atopic dermatitis in Japan
by: Masako Matsutani, et al.
Published: (2020)